High hopes for President Obama’s Indian visit for pharma

23 January 2015

This January 26, India's Republic Day is set to be a momentous one with the country hosting the US President Barack Obama as the chief guest for the parade, reports The Pharma Letter’s India correspondent.

Obamacare has brought in massive changes in the way generic consumption has taken place in the USA, with sources indicating that some positive announcements are expected for India's pharma industry during Obama's second visit to the country as a serving President.

US Secretary of State John Kerry's visit to India last week, to attend the Vibrant Gujarat summit, has also been termed a harbinger of good times. The US was a partner country for the first time, and Kerry’s trip has set the stage for a new round of talks during Obama’s visit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >